gip vs glp 1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology ๐ https://bit.ly/4p18nLz Curious how GLP-1
Description
Among individuals with obesity, MASLD prevalence exceeds 75%, whereas type 2 diabetes is associated with MASLD in 55%-70% of cases
The safest approach centers on sustainable fat loss support: achieving a modest caloric deficit driven by a nutrient-dense, high-protein, high-fiber diet, combined with regular strength training and close monitoring of your metabolic health markers
Of those, 4 RCTs [1, 2, 4] as SURMONT-OSA Trial by Malhotra et al
43% of people diagnosed with diabetes in the U.S
[PubMed] [Google Scholar] 12.Ui M., Claus T.H., Exton J.H., Park C.R
